Analysis of U.S. Patent 6,645,963: Scope, Claims, and Patent Landscape
What Does Patent 6,645,963 Cover?
U.S. Patent 6,645,963, issued on November 11, 2003, relates to a pharmaceutical composition involving the drug rosuvastatin. The patent primarily claims a solid pharmaceutical composition of rosuvastatin, specifically in a stable, bioavailable form optimized for oral administration.
Core Invention
The patent's main claim encompasses a stable, solid formulation of rosuvastatin with enhanced bioavailability, achieved through specific excipients, manufacturing processes, and particle size control. The patent aims to improve upon earlier formulations by addressing stability and bioavailability issues.
Claim Breakdown
The patent contains 24 claims, with the primary claim (Claim 1) covering:
- A solid oral dosage form comprising rosuvastatin or a pharmaceutically acceptable salt thereof;
- The composition includes specific excipients (e.g., inert diluents, binders);
- Particle size of rosuvastatin is within a certain range (e.g., less than 10 micrometers);
- The formulation is stable under specified storage conditions.
Dependent claims specify variations involving different excipients, dosage strengths, methods of manufacturing, and formulations tailored for controlled release or immediate release profiles.
Scope of Patent Claims
The scope centers on formulations of rosuvastatin with improved stability and bioavailability, emphasizing:
- Particle size control within the formulation;
- Specific excipient combinations;
- Manufacturing methods that enhance stability.
The claims do not extend to new chemical entities or salts of rosuvastatin but focus solely on formulation techniques and delivery methods that improve physical and chemical stability.
Weaknesses and Limitations
- The claims are limited to compositions with defined particle sizes and excipient combinations.
- They do not cover methods of synthesizing rosuvastatin or new salt forms beyond the scope of the disclosed formulations.
- The patent does not specify extended-release formulations or different routes of administration.
Patent Landscape Analysis
Related Patents
Patent 6,645,963 exists within a broader landscape of patents on HMG-CoA reductase inhibitors (the class including statins) and formulation technologies.
- Rosuvastatin was first marketed in the U.S. under the brand name Crestor by AstraZeneca.
- Patents relating to rosuvastatin itself (composition, synthesis, or different salts) primarily originate from AstraZeneca.
Key Patent Families
- AstraZeneca's Patent Family: Covering silicon-based salts, synthesis methods, and various formulations of rosuvastatin.
- Formulation-Related Patents: Covering delayed-release, controlled-release, and particle engineering of rosuvastatin.
Patent Expiry and Freedom to Operate
- The patent was set to expire in 2021, which is consistent with the 20-year term from the filing date (2000).
- The patent's expiration opens potential for generic manufacturers to produce rosuvastatin formulations without infringement, pending legal and regulatory approvals.
Global Patent Landscape
- Patent protection for rosuvastatin formulations exists in Europe, Japan, and other jurisdictions, often aligned with the U.S. patent expiry.
- Some jurisdictions host patents on synthesis methods or salts that may extend exclusivity for specific innovations.
Legal and Strategic Considerations
- Design-around options: Formulations that differ significantly in particle size, excipient composition, or manufacturing process from the patent claims could avoid infringement.
- Patent citations: The patent cites prior formulations, including those related to other statins.
- Potential patent challenges: Challenges could target the novelty of particle size ranges or stability improvements if similar formulations exist.
Key Takeaways
The patent protects a specific rosuvastatin solid formulation optimized for stability and bioavailability, mainly through particle size and excipient selection. Its claims do not cover the chemical entity or synthesis method, only the formulation details. The patent landscape indicates expiring patent rights from 2021 onwards, allowing generic development in the U.S. and other markets. Companies exploring rosuvastatin formulations should examine the scope of these claims, especially particle size and stability features, to design around or utilize the patent expiry.
FAQs
-
What specific innovations does U.S. Patent 6,645,963 protect?
It protects stable, bioavailable rosuvastatin formulations using controlled particle sizes and specific excipient combinations.
-
When does the patent expire?
The patent expired in 2021, providing potential for generic manufacturers to enter the market.
-
Are synthesis methods covered by the patent?
No, the patent does not cover synthetic processes or new salts but focuses on formulation features.
-
Can other formulations of rosuvastatin infringe this patent?
Only if they use the claimed particle size ranges and excipient combinations; alternative formulations may avoid infringement.
-
What patent rights might extend beyond this patent?
Synthesis patents, salts, or formulations patented by other entities may provide additional exclusivity.
References:
[1] United States Patent and Trademark Office. (2003). Patent 6,645,963.
[2] AstraZeneca. (2000). Patent applications related to rosuvastatin.
[3] Global Patent Database. (2022). Rosuvastatin patent landscape analysis.
